Allison Clemens
April
ababaabhay
achoi2392
adhoward1

2025 PACUPrep BCCCP Preparatory Course Calcium and Magnesium Abnormalities Advanced Pharmacologic Strategies for Calcium and Magnesium Repletion and Removal

Lesson 91, Topic 3

In Progress

← Previous

Advanced Pharmacologic Strategies for Calcium and Magnesium Repletion and Removal

Lesson Progress

0% Complete

Advanced Pharmacologic Strategies for Calcium and Magnesium

Objective

Design an evidence-based, escalating pharmacotherapy plan for critically ill patients with calcium and magnesium abnormalities.

I. Management of Hypocalcemia

Prompt correction of ionized hypocalcemia is critical to restore cardiac stability and neuromuscular function. Agent selection hinges on severity, clinical presentation, and available intravenous access.

Comparison of Intravenous Calcium Formulations
Feature	Calcium Gluconate (10%)	Calcium Chloride (10%)
Elemental Calcium	90 mg per 10 mL ampule	270 mg per 10 mL ampule (3x more potent)
Primary Indication	Symptomatic or moderate-severe hypocalcemia (ionized Ca <1.00 mmol/L)	Life-threatening hypocalcemia with hemodynamic instability or arrhythmias
Route of Administration	Peripheral or Central Line	CENTRAL LINE ONLY
Standard Dosing	1–2 g IV over 10–20 minutes	500–1,000 mg IV over 5–10 minutes
Key Warning	Extravasation causes tissue injury; less severe than chloride.	Extravasation causes severe tissue necrosis. High risk of arrhythmia if pushed too fast.
Clinical Niche	Workhorse agent for routine repletion.	Emergency rescue for severe cases with secure central access.

Continuous vs. Bolus Infusion

A continuous infusion of calcium gluconate (e.g., 0.5–1 g/h) can be considered to smooth out fluctuations in ionized calcium levels. However, this approach lacks strong outcome data and should generally be reserved for patients who fail to maintain target levels despite repeated intermittent boluses.

II. Management of Hypomagnesemia

Hypomagnesemia can precipitate refractory hypokalemia, cardiac arrhythmias (including torsades de pointes), and neuromuscular irritability. Intravenous magnesium sulfate is the first-line therapy.

Dosing of Intravenous Magnesium Sulfate
Severity	Serum Mg Level	Recommended IV Dose
Mild / Asymptomatic	1.0–1.2 mg/dL	2 g IV over 1 hour
Severe / Symptomatic	<1.0 mg/dL	4–6 g IV over 12-24 hours (e.g., 0.05–0.15 g/kg/day)
Torsades de Pointes	Any level (with arrhythmia)	2 g IV push over 1-2 minutes, followed by infusion

Monitoring & Adjustments: Monitor serum magnesium every 6–12 hours. Check deep tendon reflexes, blood pressure, and heart rate, especially with higher infusion rates (max 1 g/h to avoid hypotension). Reduce dose by 50% if CrCl <30 mL/min.

The Magnesium-Potassium Link

Always check a magnesium level when treating hypokalemia. Magnesium is a crucial cofactor for the renal outer medullary potassium (ROMK) channel, which regulates potassium secretion. In a state of hypomagnesemia, these channels “leak” potassium, making repletion efforts futile. Correcting the magnesium deficit is often the key to resolving refractory hypokalemia.

III. Management of Hypercalcemia

Acute management focuses on restoring volume, promoting renal calcium excretion, and inhibiting bone resorption. The choice of therapy depends on the desired speed of onset and duration of effect.

Figure 1. Treatment Algorithm for Hypercalcemia. The strategy begins with universal therapies (hydration, diuresis) and then adds agents based on the need for rapid vs. sustained calcium lowering.

IV. Management of Hypermagnesemia

Symptomatic or severe hypermagnesemia is a medical emergency requiring immediate antagonism of its cardiotoxic and neuromuscular effects, followed by definitive removal if necessary.

Therapies for Severe Hypermagnesemia
Intervention	Mechanism	Indication
IV Calcium Gluconate	Directly antagonizes the membrane effects of magnesium.	First-line for any symptomatic patient (hypotension, bradycardia, respiratory depression, loss of reflexes).
Hemodialysis	Efficiently removes magnesium from circulation.	Definitive therapy for severe cases (Mg >12 mg/dL), refractory symptoms, or anuric renal failure.

V. Special Populations and PK/PD Adjustments

Critically ill patients often have altered pharmacokinetics that necessitate dosing adjustments for electrolytes.

CRRT and ECMO

Continuous Renal Replacement Therapy (CRRT): Both calcium and magnesium are cleared steadily by CRRT. Empirically increase continuous infusion rates by 10–20% and monitor levels frequently to maintain therapeutic targets.
Extracorporeal Membrane Oxygenation (ECMO): Data are limited, but sequestration of ions in the circuit can occur. Monitor ionized levels every 6 hours after initiation and adjust infusions based on trends.

Sepsis and Edema

Patients with sepsis or significant edema have an increased volume of distribution (Vd) for hydrophilic ions like calcium and magnesium. This may necessitate larger initial loading doses to achieve target serum concentrations. Reassess levels more frequently (e.g., every 4 hours) during the initial resuscitation phase.

The Importance of Ionized Calcium

Always use the ionized calcium level for clinical decision-making. In patients with hypoalbuminemia, the total calcium level is unreliable as protein binding is reduced, increasing the free, physiologically active fraction. While a correction formula exists (Corrected Ca = Total Ca + 0.8 × [4 – albumin]), it is only an estimate. Direct measurement of ionized calcium is the standard of care.

VI. Pharmacoeconomics and Formulary Considerations

Optimizing ICU resources requires balancing agent cost with the costs of monitoring, administration, and potential complications.

Cost and Resource Considerations
Factor	Calcium Gluconate	Calcium Chloride
Acquisition Cost (Approx.)	$2–$5 per 10 mL ampule	$3–$7 per 10 mL ampule
Hidden Costs	Lower risk of complications.	Requires central line placement (~$200-500) and carries higher risk of catastrophic extravasation.
Nursing Workload	Safer for peripheral administration, less intensive site monitoring.	Requires central line care and vigilant monitoring during infusion.

VII. Clinical Pitfalls and Practice Pearls

Anticipating common errors and embedding best practices into daily workflow can significantly improve patient safety.

Pitfall: Preventing Extravasation Injury

Calcium extravasation is a preventable iatrogenic injury. To minimize risk:

NEVER administer calcium chloride peripherally.
For peripheral administration, dilute 10% calcium gluconate in a larger volume (e.g., 1-2g in 50-100mL of D5W or NS).
Inspect the IV site meticulously before, during (every 5-10 minutes), and after the infusion.
Use a large, patent vein and avoid sites near joints or in the hand/wrist if possible.

Pearl: Proactive and Coordinated Care

Anticipate Tachyphylaxis: When starting calcitonin for hypercalcemia, expect its effect to wane after 48 hours. Plan for bisphosphonate administration early to ensure a smooth transition and sustained control.
Communicate Clearly: Involve nephrology early for potential RRT in severe hypercalcemia or hypermagnesemia. Explicitly state target ionized calcium and magnesium levels in daily rounds and handoffs. Alert nursing to key signs of toxicity (e.g., hypotension with magnesium, ECG changes with calcium).

References

Dickerson RN. Fluids, Electrolytes, Acid-Base Disorders, and Nutrition Support. In: ACCP/SCCM Critical Care Pharmacy Review. 2016.
Dickerson RN, Morgan LM, Kuhl DA, et al. Treatment of moderate to severe acute hypocalcemia in critically ill trauma patients. JPEN J Parenter Enteral Nutr. 2007;31(3):228–233.
Dickerson RN, Miller PL, Hinds WR, et al. Treatment of moderate to severe acute hypomagnesemia in critically ill adults. Crit Care Med. 1996;24(1):38–45.
Hawkins F, Hockaday A. Emergency management of acute hypercalcaemia in adults. Clin Med (Lond). 2016;16(5):455–459.
Goltzman D. Approach to Hypercalcemia. In: Feingold KR, Anawalt B, Blackman MR, et al., eds. Endotext. MDText.com, Inc.; 2019.
Cascella M, Vaqar S. Hypermagnesemia. In: StatPearls. StatPearls Publishing; 2022.
Bui-Thi HD, Ridel C, Hie M, et al. Management of hypercalcemic crisis by continuous renal replacement therapy: a case report and a literature review. Ther Adv Endocrinol Metab. 2025;16.
de Baaij JHF, Hoenderop JGJ, Bindels RJM. Magnesium in Man: Implications for Health and Disease. Physiol Rev. 2015;95(1):1–46.

2025 PACUPrep BCCCP Preparatory Course

Pulmonary

Participants 432